Clinical trials: ALK- Anaplastic Large Cell Lymphoma (ALCL)
Anaplastic Lymphoma Kinase Positive (ALK +) Anaplastic Large Cell Lymphoma, Inflammatory Myofibroblastic Tumors
Pharmacokinetics, Safety, and Efficacy of Brigatinib Monotherapy in Pediatric and Young Adult Participants With ALK+ Anaplastic Large Cell Lymphoma, Inflammatory Myofibroblastic Tumors or Other Solid Tumors
The purpose of this study is to estimate the maximum tolerated dose (MTD)/ recommended phase 2 dose (RP2D) regimen and characterize the pharmacokinetics (PK) of brigatinib monotherapy (film-coated tablets and age-appropriate…
- Conditions
- Anaplastic Lymphoma Kinase Positive (ALK +) Anaplastic Large Cell Lymphoma, Inflammatory Myofibroblastic Tumors, Solid Tumors
- Trial name
- NCT04260009
- Testing
- Brigatinib, Brigatinib AAF
- Sponsor
- Takeda
Relapsing/Refractory ALK+ Anaplastic Large Cell Lymphoma
Nivolumab for Pediatric and Adult Relapsing/Refractory ALK+, for Evaluation of Response in Patients With Progressive Disease (Cohort 1) or as Consolidative Immunotherapy in Patients in Complete Remission After Relapse (Cohort 2)
Prospective, non-randomized, single arm phase II trial with 2 cohorts of ALK+ ALCL treated with nivolumab
- Trial name
- NIVO-ALCL (NCT03703050)
- Testing
- Nivolumab cohort 1, Nivolumab cohort 2
- Where
- 13 sites in Denmark, France and 1 more
- Volunteers
- 45 people
- Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
CD30-Positive Diffuse Large B-Cell Lymphoma, Anaplastic Large Cell Lymphoma, T Cell and Null Cell Type
Constitutive IL7R (C7R) Modified Banked Allogeneic CD30.CAR EBVSTS for CD30-Positive Lymphomas
This study involves patients with diffuse large B cell lymphoma (DLBCL), natural killer/T-cell lymphoma (NKTL), or classical Hodgkin lymphoma (cHL) (referred to collectively as lymphoma) whose disease has returned or not…
- Conditions
- CD30-Positive Diffuse Large B-Cell Lymphoma, Anaplastic Large Cell Lymphoma, T Cell and Null Cell Type, Anaplastic Large Cell Lymphoma, ALK-Positive, Peripheral T-cell Lymphoma
- Trial name
- CABAL2 (NCT06176690)
- Testing
- C7R.CD30.CAR-EBVST cells
- Where
- 2 sites in United States
- Volunteers
- 90 people
- Sponsor
- Baylor College of Medicine
Anaplastic Large Cell Lymphoma, ALK-Positive
Chemoimmunotherapy for ALK+ Relapsed/Refractory ALCL
Children, adolescents, and young adults (CAYA) with relapsed/refractory (R/R) high-risk ALK+ Anaplastic Large Cell Lymphoma (ALCL) have a low incidence of overall survival.
- Trial name
- ACCELERATE (NCT07013565)
- Testing
- Vinblastine (Velban), Brentuximab vedotin (Adcetris), Nivolumab (Opdivo)
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- New York Medical College
Anaplastic Large Cell Lymphoma
BV-CHP Real-life and Biological Evidences in Patients With sALCL
Systemic Anaplastic Large Cell Lymphomas (sALCL) are rare lymphomas for which the cooperation in the collection of biological and clinical data is necessary to improve knowledge on the disease.
- Trial name
- FIL_BREAL (NCT07467317)
- Where
- 19 sites in Italy
- Volunteers
- 100 people
- Sponsor
- Fondazione Italiana Linfomi - ETS
Relapsed or Refractory T-cell Lymphomas
A Study to Assess the Safety, Tolerability, Efficacy, and Drug Levels of BMS-986369 (Golcadomide) in Participants With Relapsed or Refractory T-cell Lymphomas in Japan (GOLSEEK-3)
The purpose of this study is to test the safety, tolerability, efficacy, and drug levels of BMS-986369 (Golcadomide) in participants with relapsed or refractory T-cell lymphomas in Japan (GOLSEEK-3).
- Trial name
- NCT06035497
- Testing
- BMS-986369
- Where
- 40 sites in Japan
- Volunteers
- 83 people
- Sponsor
- Bristol-Myers Squibb
Locally Advanced and/or Metastatic Anaplastic Large Cell Lymphoma, Locally Advanced and/or Metastatic Inflammatory Myofibroblastic Tumor
CREATE: Cross-tumoral Phase 2 With Crizotinib
The study will primarily assess the antitumor activity of crizotinib in a variety of tumors with alterations in ALK and/or MET pathways.
- Conditions
- Locally Advanced and/or Metastatic Anaplastic Large Cell Lymphoma, Locally Advanced and/or Metastatic Inflammatory Myofibroblastic Tumor, Locally Advanced and/or Metastatic Papillary Renal Cell Carcinoma Type 1, Locally Advanced and/or Metastatic Alveolar Soft Part Sarcoma
- Trial name
- CREATE (NCT01524926)
- Testing
- Crizotinib (PF-02341066)
- Where
- 25 sites in Belgium, France and 8 more
- Volunteers
- 582 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Maintenance Treatment of Peripheral T-cell Lymphoma
Golidocitinib Versus Placebo as Maintenance Therapy for Peripheral T-Cell Lymphoma
This is a multicenter, randomized, double-blind, placebo-controlled phase III trial evaluating golidocitinib as maintenance therapy in adult patients with peripheral T-cell lymphoma (PTCL) who achieved complete response (CR) or…
- Trial name
- T-START-M1 (NCT07300514)
- Testing
- PET-CTandct- DNAdetection, golidocitinib
- Where
- China
- Volunteers
- 136 people
- Sponsor
- Fudan University
Peripheral T-Cell Lymphoma, Not Otherwise Specified, Angioimmunoblastic T-cell Lymphoma
Risk Stratification of Nodal PTCL
This study is to investigate the prognostic significance of enhanced International Prognostic Index (NCCN-IPI) and post-treatment PET results in patients with newly diagnosed nodal peripheral T-cell lymphoma (PTCL), and establish…
- Conditions
- Peripheral T-Cell Lymphoma, Not Otherwise Specified, Angioimmunoblastic T-cell Lymphoma, Anaplastic Large Cell Lymphoma, ALK-negative
- Trial name
- NCT03040206
- Where
- South Korea
- Volunteers
- 405 people
- Sponsor
- Chonbuk National University Hospital
Anaplastic Large Cell Lymphoma, ALK-Positive
Prospective Study of the Prognostic Value of New Markers in Adults With ALK-positive Large Anaplastic Lymphoma
The study aims to evaluate the prognostic value on the complete metabolic response rate (MCR), the incidence of relapse / progression, the Progression Free Survival (PFS) and the Overall Survival (OS).
- Trial name
- NCT03603847
- Where
- 15 sites in France
- Volunteers
- 41 people
- Sponsor
- The Lymphoma Academic Research Organisation
Peripheral T-Cell Lymphoma (PTCL NOS), Nodal T-follicular Helper Cell Lymphoma
Aclarubicin Plus Cyclophosphamide, Vincristine, and Prednisone (CAOP) in Patients With Previously Untreated Peripheral T-Cell Lymphoma
Peripheral T-cell lymphomas (PTCLs) are a heterogeneous group of rare disorders that result from clonal proliferation of mature post-thymic lymphocytes. These T-cell neoplasms account for approximately 10-15% of all lymphomas.
- Conditions
- Peripheral T-Cell Lymphoma (PTCL NOS), Nodal T-follicular Helper Cell Lymphoma, Anaplastic Large Cell Lymphoma (ALCL) (ALK-1 Negative)
- Trial name
- NCT07535762
- Testing
- Aclarubicin, Cyclophosphamide, Vincristine
- Where
- 2 sites in China
- Volunteers
- 36 people
- Sponsor
- Shanghai Jiao Tong University School of Medicine
Non-GCB/ABC Diffuse Large B-Cell Lymphoma, High-grade B-cell Lymphoma
Tislelizumab in Combination With Lenalidomide in Refractory and Relapsed Elderly Patients With Non-GCB DLBCL
Aim of this study will evaluate the efficacy and safety of tislelizumab in combination with lenalidomide in in patients with relapsed or refractory Elderly Patients with non-GCB Diffuse Large B Cell Lymphoma
- Conditions
- Non-GCB/ABC Diffuse Large B-Cell Lymphoma, High-grade B-cell Lymphoma, Follicular Lymphoma Grade IIIb, Transformed Lymphoma
- Trial name
- NCT04796857
- Testing
- PD-1 Antibody, Lenalidomide
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Huiqiang Huang
Peripheral T Cell Lymphoma Unspecified, Anaplastic Large Cell Lymphoma, ALK-negative
RAD001 Combined With CHOP in Newly Diagnosed Peripheral T-cell Lymphomas
The urgent need for new effective therapy for T-cell lymphoma patients and promising results observed so far in trials with RAD001(everolimus, mTOR inhibitor) strongly warrants the investigation of RAD001 combined with CHOP as a…
- Conditions
- Peripheral T Cell Lymphoma Unspecified, Anaplastic Large Cell Lymphoma, ALK-negative, Angioimmunoblastic T Cell Lymphoma, Cutaneous T Cell Lymphoma
- Trial name
- RADCHOP (NCT01198665)
- Testing
- RAD001 (Everolimus)
- Where
- 5 sites in South Korea
- Volunteers
- 46 people
- Sponsor
- Samsung Medical Center
Blastic Plasmacytoid Dendritic Cell Neoplasm, Hepatosplenic T-Cell Lymphoma
Nivolumab in Treating Patients With Relapsed or Refractory Peripheral T-cell Lymphoma
This phase II trial studies how well nivolumab works in treating patients with peripheral T-cell lymphoma that has come back after a period of improvement or that does not respond to treatment.
- Conditions
- Blastic Plasmacytoid Dendritic Cell Neoplasm, Hepatosplenic T-Cell Lymphoma, HTLV-1 Infection, NK-Cell Lymphoma, Unclassifiable
- Trial name
- NCT03075553
- Testing
- Laboratory Biomarker Analysis, Nivolumab
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Mayo Clinic
Haematological Malignancy, Malignant Neoplasm
DETERMINE Trial Treatment Arm 01: Alectinib in Adult, Paediatric and Teenage/Young Adult Patients With ALK Positive Cancers
This clinical trial is looking at a drug called alectinib. Alectinib is approved as standard of care treatment for adult patients with certain types of lung cancer.
- Conditions
- Haematological Malignancy, Malignant Neoplasm, Lymphoproliferative Disorders, Neoplasms by Histologic Type
- Trial name
- DETERMINE (NCT05770037)
- Testing
- Alectinib
- Where
- 27 sites in United Kingdom
- Volunteers
- 30 people
- Sponsor
- Cancer Research UK
Anaplastic Large Cell Lymphoma, ALK-Negative, Anaplastic Large Cell Lymphoma, ALK-Positive
Combination Chemotherapy & Lenalidomide in Newly Diagnosed Stage II-IV Peripheral T-cell Non-Hodgkin's Lymphoma
This phase I/II trial studies the side effects and best dose of lenalidomide when given together with combination chemotherapy and to see how well they work in treating patients with newly diagnosed stage II-IV peripheral T-cell…
- Conditions
- Anaplastic Large Cell Lymphoma, ALK-Negative, Anaplastic Large Cell Lymphoma, ALK-Positive, Hepatosplenic T-Cell Lymphoma, Peripheral T-Cell Lymphoma, Not Otherwise Specified
- Trial name
- NCT02561273
- Testing
- Autologous Hematopoietic Stem Cell Transplantation, Cyclophosphamide, Doxorubicin Hydrochloride
- Where
- 8 sites in United States
- Volunteers
- 54 people
- Sponsor
- University of Nebraska
ALCL
Study of the Biological Mechanisms Associated With the Immunogenicity in Anaplastic Large Cell Lymphoma ( ALCL ) ALK +
To study the correlation between the polymorphism of the main immunity genes and progression-free survival in ALCL of the child.
- Trial name
- Immuno ALCL (NCT02902874)
- Testing
- Blood sample
- Where
- France
- Volunteers
- 185 people
- Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
ALK-negative Anaplastic Large Cell Lymphoma, Peripherial T Cell Lymphoma,Not Otherwise Specified
CTOP/ITE/MTX Compared With CHOP as the First-line Therapy for Newly Diagnosed Young Patients With T Cell Lymphoma
T cell lymphoma is a heterogenic malignancy with poor outcome. Five-year PFS and OS of the patients recieved classic CHOP regimen(cyclophosphamide,vincristin,doxorubicin and predisone)is less than 30%.High dose intensive…
- Conditions
- ALK-negative Anaplastic Large Cell Lymphoma, Peripherial T Cell Lymphoma,Not Otherwise Specified, Angioimmunoblastic T Cell Lymphoma, Enteropathy Associated T Cell Lymphoma
- Trial name
- NCT01746992
- Testing
- Cyclophosphamide 750mg/m2, Vincristine 1.4mg/m2, Doxorubicin 50mg/m2
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Ruijin Hospital
Anaplastic Large Cell Lymphoma, ALK-Positive, Ann Arbor Stage II Noncutaneous Childhood Anaplastic Large Cell Lymphoma
Brentuximab Vedotin or Crizotinib and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II-IV Anaplastic Large Cell Lymphoma
This partially randomized phase II trial studies how well brentuximab vedotin or crizotinib and combination chemotherapy works in treating patients with newly diagnosed stage II-IV anaplastic large cell lymphoma.
- Conditions
- Anaplastic Large Cell Lymphoma, ALK-Positive, Ann Arbor Stage II Noncutaneous Childhood Anaplastic Large Cell Lymphoma, Ann Arbor Stage III Noncutaneous Childhood Anaplastic Large Cell Lymphoma, Ann Arbor Stage IV Noncutaneous Childhood Anaplastic Large Cell Lymphoma
- Trial name
- NCT01979536
- Testing
- Brentuximab Vedotin, Crizotinib, Cyclophosphamide
- Where
- 154 sites in United States
- Volunteers
- 137 people
- Sponsor
- National Cancer Institute (NCI)
ALK-Positive Anaplastic Large Cell Lymphoma
Crizotinib Combined With Etoposide Capsule Followed by Auto-HSCT for Relapsed and Refractory ALK+ ALCL
To observe the safety, tolerability and clinical effects of crizotinib combined with etoposide capsule followed by autologous hematopoietic stem cell transplantation (Auto-HSCT) for patients with relapsed and refractory…
- Trial name
- NCT03707847
- Testing
- Crizotinib, Etoposide Capsule, Auto-HSCT
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Mingzhi Zhang